CGEM - NASDAQ
Cullinan Therapeutics, Inc.
$15.21
-0.85%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotCullinan Therapeutics, Inc. Management Team
Dr. Corinne Savill Ph.D.
Chief Business Officer
Ms. Mary Kay Fenton CPA
Chief Financial Officer
Compensation
$544,153
Mr. Steve Andre
Chief Human Resources Officer
Ms. Jacquelyn L. Sumer J.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.
Chief Medical Officer
Compensation
$844,826
Dr. Jennifer Michaelson Ph.D.
Chief Scientific Officer
Mr. Kevin A. Johnston
Chief Technical Operations Officer
Dr. Patrick A. Baeuerle Ph.D.
Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Compensation
$763,734
Mr. Nadim Ahmed
President, Chief Executive Officer & Director
Compensation
$1,173,806
Ms. Rose Weldon
Senior Vice President of Corporate Affairs
Cullinan Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.32M and sold $1.13M worth of CGEM shares, resulting in $12.19M of net buying activity.
3 Months
0
0.00
7.8K
113.88K
-114K
-$114K
3-6 Months
0
0.00
75.4K
971.90K
-972K
-$972K
6-9 Months
1.9M
13.32M
4.0K
49.20K
+13.3M
+$13.27M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Lynx1 Capital Management Lp
10 Percent Owner
$13.32M
Top Sellers
Michaelson Jennifer
Officer: Chief Scientific Officer
$575K
Ahmed Nadim
Director, Officer: President And Ceo
$295K
Jones Jeffrey Alan
Officer: Chief Medical Officer
$179K
Sumer Jacquelyn L
Officer: Chief Legal Officer
$86K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $12.19M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
CGEM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | April 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 16, 2024 | June 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 25, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.